Consun Pharmaceutical Group Limited (FRA:C1P)

Market Cap	1.32B +46.3%
Revenue (ttm)	416.13M +15.2%
Net Income	131.27M +18.4%
EPS	0.15 +15.6%
Shares Out	n/a
PE Ratio	10.09
Forward PE	8.38
Dividend	0.07 (4.68%)
Ex-Dividend Date	Sep 4, 2025

Volume	n/a
Open	1.490
Previous Close	1.510
Day's Range	1.490 - 1.510
52-Week Range	1.020 - 2.180
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About FRA:C1P

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiol...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 3,115
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: C1P

Financial Performance

In 2025, FRA:C1P's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY